"An experimental oral lymphocyte trafficking agent, ozanimod (Receptos), showed modest activity against ulcerative colitis (UC) in a small, early-stage clinical trial.
In the double-blind, placebo-controlled phase 2 trial in adults wit"...
GIAZO is indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older.
Limitations Of Use
- Effectiveness of GIAZO in the treatment of female patients was not demonstrated in clinical trials [see Clinical Trials].
- Safety and effectiveness of GIAZO therapy beyond 8 weeks have not been established.
DOSAGE AND ADMINISTRATION
The dose is three 1.1 g GIAZO tablets to be taken 2 times a day with or without food (6.6 g per day) for up to 8 weeks.
Dosage Forms And Strengths
GIAZO is available as yellow, oval, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.
Storage And Handling
GIAZO is available as oval, yellow, film-coated tablets containing 1.1 g balsalazide disodium, with BZT debossed on one side of the tablet.
Bottles of 180 Tablets NDC 65649-102-02
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature].
Manufactured for: Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LC Bridgewater, NJ 08807 USA. Revised: June 2016This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/28/2016
Additional Giazo Information
- Giazo Drug Interactions Center: balsalazide oral
- Giazo Side Effects Center
- Giazo FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Find out what women really need.